Related Experiment Videos
A rationale for combined therapy with a calcium channel blocker and a statin: evaluation of basic and clinical
1Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. rpmason@elucidaresearch.com
Insights
Calcium channel blockers and HMG-CoA reductase inhibitors offer cardiovascular protection beyond lowering blood pressure and lipids. These drugs may prevent cardiovascular events through pleiotropic effects like improving nitric oxide bioavailability and reducing inflammation.
Area of Science:
- Cardiovascular pharmacology and atheroprotection.
Background:
- Calcium channel blockers (CCBs) and HMG-CoA reductase inhibitors (statins) are standard treatments for hypertension and dyslipidemia.
- Their cardiovascular benefits are primarily attributed to blood pressure and lipid reduction.
Purpose of the Study:
- To review evidence for pleiotropic (non-traditional) effects of CCBs and statins in cardiovascular disease.
- To explore potential atheroprotective mechanisms beyond risk factor management.
Main Methods:
- Review of basic science and clinical trial data on CCBs and statins.
- Analysis of proposed mechanisms including nitric oxide bioavailability, anti-inflammatory activity, and oxidative stress inhibition.
Main Results:
- Emerging evidence suggests CCBs and statins provide cardiovascular benefits beyond lipid and blood pressure lowering.
- Pleiotropic effects such as enhanced endothelial function, reduced inflammation, and antioxidant properties are implicated.
Conclusions:
- CCBs and statins may offer significant atheroprotection through mechanisms independent of their primary lipid- and blood pressure-lowering effects.
- Further research into these pleiotropic actions could reveal synergistic therapeutic strategies for cardiovascular event prevention.
Abstract:
Calcium channel blockers and HMG-CoA reductase inhibitors are widely used for the management of hypertension and dyslipidemia, respectively. The use of these agents in the prevention and treatment of cardiovascular disease remains largely based on their actions in lowering blood pressure and lipids. Recent clinical trials, however, indicate that certain members of these two drug classes may slow progression of disease to an extent that cannot be solely attributed to risk factor reduction. The proposed mechanisms for such pleiotropic actions include enhancement of endothelial-dependent nitric oxide bioavailability, anti-inflammatory activity, and inhibition of oxidative stress. To understand the basis for such effects, along with potential synergies, we will review the basic and clinical evidence that indicate a broader opportunity for treatment and protection of cardiovascular events by atheroprotection with these agents beyond risk factor management.
Related Concept Videos
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:18Antihypertensive Drugs: Action of Calcium Channel Blockers
01:26Atherosclerosis III: Management
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
01:27Coronary Artery Disease V: Interprofessional Care
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT